IBI939
innovent biologics
['nsclc', 'sclc', 'innovent']
#innovent presents phase ib clinical data of #ibi939 (#antitigit #monoclonalantibody) in previously untreated #pdl1 selected #nsclc at the #esmoio22 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.